Public Employees Retirement System of Ohio Invests $1.23 Million in Xencor, Inc. (NASDAQ:XNCR)

Public Employees Retirement System of Ohio bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 53,397 shares of the biopharmaceutical company's stock, valued at approximately $1,227,000. Public Employees Retirement System of Ohio owned about 0.08% of Xencor as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Sterling Capital Management LLC lifted its holdings in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares during the last quarter. KBC Group NV lifted its holdings in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 813 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,337 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Xencor by 22.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after purchasing an additional 1,282 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Xencor by 132.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 4,482 shares during the last quarter.

Insider Transactions at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.76% of the company's stock.

Xencor Price Performance

Shares of XNCR traded up $0.53 during midday trading on Friday, reaching $9.65. The stock had a trading volume of 525,116 shares, compared to its average volume of 665,850. Xencor, Inc. has a 52 week low of $7.16 and a 52 week high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm's 50 day moving average price is $8.98 and its 200-day moving average price is $15.71. The company has a market capitalization of $686.80 million, a P/E ratio of -3.02 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. During the same period in the prior year, the firm posted ($1.11) EPS. The firm's quarterly revenue was up 104.6% on a year-over-year basis. On average, analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

XNCR has been the topic of several recent research reports. William Blair initiated coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Barclays cut their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Finally, Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.50.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.